Sunday, January 29, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Featured News

NIH: Vaccines Protect Monkeys Against Zika Infection

by Global Biodefense Staff
August 25, 2016
Biodefense Vaccine Development

Credit: Shutterstock, modified by Global Biodefense

The National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) is supporting research and development of multiple Zika vaccine candidates.

Dr. Dan H. Barouch leads a research team at Harvard Medical School and Beth Israel Deaconess Medical Center that is collaborating with scientists at Walter Reed Army Institute of Research and the University of São Paulo. They previously showed progress developing Zika vaccines in mice. In their latest study, they tested 3 different vaccine approaches in rhesus macaques, an important animal model. Results appeared online on August 4, 2016, in Science.

The researchers first tested an inactivated Zika virus vaccine in 16 rhesus macaques. Half the animals received the experimental vaccine and half a placebo injection. Within 2 weeks after the initial injection, all vaccinated animals developed antibodies to the Zika virus. A second dose given 4 weeks later substantially boosted antibody levels.

When the monkeys were exposed to Zika virus, the group that received the placebo injections developed high levels of virus in blood and other tissues for 6 to 7 days. Vaccinated animals had no detectable virus and showed no other evidence of infection.

In another experiment, the team tested 2 vaccines designed to trigger an immune response against the viral envelope protein, a key vaccine target on the Zika virus. The scientists administered 2 doses of an experimental DNA vaccine, 1 dose of an experimental adenovirus vector vaccine, or a placebo injection to 3 groups of 4 monkeys each. The group that received the DNA vaccine received a booster shot 4 weeks later.

The researchers detected significant Zika-neutralizing antibodies in the animals after the second DNA vaccine injection. The adenovirus vector-based vaccine induced Zika-specific neutralizing antibodies 2 weeks after the single injection.

The monkeys were exposed to Zika virus 4 weeks after the final vaccinations. Both the DNA and adenovirus vector vaccines provided complete protection against infection. None of the vaccines produced adverse side effects.

“Three vaccines provided complete protection against Zika virus in nonhuman primates, which is the best animal model prior to starting clinical trials,” Barouch says. “The consistent and robust protection against Zika virus in both rodents and primates fuels our optimism about the development of a safe and effective Zika vaccine for humans.”

Read more: Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys.

Tags: Emerging ThreatsVaccinesWRAIRZika

Related Posts

DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
How Are Bivalent COVID Vaccines Stacking Up Against Omicron?
Infectious Diseases

How Are Bivalent COVID Vaccines Stacking Up Against Omicron?

January 12, 2023
NISTCHO: New Living Reference Material for Producing Monoclonal Antibodies
Medical Countermeasures

NISTCHO: New Living Reference Material for Producing Monoclonal Antibodies

January 12, 2023
Load More

Latest News

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023
Biodefense Headlines – 17 January 2023

Biodefense Headlines – 17 January 2023

January 17, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC